Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use
AssigneeAventis Pharma Deutschland GmbH
InventorKenneth J. Clemeston
Life of this patent
Estimating the term…
Loading patent…
AssigneeAventis Pharma Deutschland GmbH
InventorKenneth J. Clemeston
Estimating the term…
The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPVI can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.
An isolated DNA coding for Glycoprotein VI which comprises the sequence set forth in SEQ ID NO:
An isolated DNA which consists of the sequence set forth in SEQ ID NO:
Dependencies are inferred from the claim text.